Evidence map›Paper›PMID 40343646›Full record

ArticleEJNMMI research2025

PSMA-expressing, fluciclovine-negative vertebral hemangioma.

Azadeh Eslambolchi, Amin Haghighat Jahromi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Azadeh EslambolchiDivision of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, 510 South Kingshighway Blvd, Campus Box 8223, St. Louis, MO, 63110, USA.
Amin Haghighat JahromiDivision of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, 510 South Kingshighway Blvd, Campus Box 8223, St. Louis, MO, 63110, USA. aminj@wustl.edu.ORCID http://orcid.org/0000-0002-8263-903X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFalse-positive findings in Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography (PSMA PET-CT) can complicate accurate staging of prostate cancer, especially in cases such as vertebral hemangiomas, a benign lesion of the spinal column. These ambiguities may result in unnecessary biopsies in patients with prostate cancer when PSMA PET findings are inconclusive. CASE PRESENTATION: We present the case of a 68-year-old male with prostate cancer who had a PSMA-expressing, fluciclovine-negative vertebral hemangioma.

conclusionThis case highlights the role of fluciclovine PET-CT in distinguishing benign vertebral hemangiomas from prostate cancer metastases, improving diagnostic accuracy specifically in positive cases of PSMA PET-CT.

Indexed as

Fluciclovine PET-CTProstate cancer stagingPSMA PET-CTVertebral hemangioma

Identifiers

PMID40343646
PMCPMC12064478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.